Cybersecurity belongs in medical device design because software, connectivity and the systems around a device can introduce vulnerabilities that affect safety and effectiveness. A security flaw can be a patient-safety flaw. In the United States, FDA treats it that way: its current guidance covers security in design, labeling and premarket documentation, and section 524B of the FD&C Act sets specific legal requirements for devices that qualify as “cyber devices.” This article covers what those requirements are, where guidance ends and law begins, and why the work continues after a device ships.
Why security is a safety question
FDA’s cybersecurity overview says medical devices are increasingly connected to the internet, hospital networks and other devices. The same connectivity that can improve care can raise cybersecurity risk, and a breach can potentially affect a device’s safety and effectiveness.
As an Amazon Associate I earn from qualifying purchases.
That is why security cannot be bolted on at the end. Authentication, encryption, update mechanisms and network behavior are design decisions that determine how a device fails, and whether it fails safely, when someone tries to misuse it. FDA is candid about the limits: “Threats and vulnerabilities cannot be eliminated and reducing cybersecurity risks is especially challenging.” It adds that “The health care environment is complex, and manufacturers, hospitals, and facilities must work together to manage cybersecurity risks.” Design aims to reduce and manage risk, not to promise it away.
Free tools Windows power users keep installed
One-click scans. No signup required.
Scope: U.S. FDA rules only
Everything below describes the U.S. FDA framework. Other jurisdictions have their own rules. Two distinctions matter throughout:
#1 Best Overall
- Statute versus guidance. Section 524B is law. FDA’s guidance expresses the agency’s recommendations and is not itself a binding regulation.
- Cyber devices versus all devices. Section 524B’s specific submission requirements apply only to devices that meet the statutory definition. Guidance on design and risk management is relevant more broadly to devices with cybersecurity risk.
What FDA’s current guidance covers
The current document is the February 2026 final guidance, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions. FDA says it gives recommendations on cybersecurity device design, labeling and premarket-submission documentation, and that it addresses section 524B. It supersedes the final guidance issued June 27, 2025, so anyone working from the earlier version should check the newer text.
What counts as a “cyber device” under section 524B
The Consolidated Appropriations Act, 2023 added section 524B to the FD&C Act, and FDA says its amendments took effect March 29, 2023. FDA describes a cyber device as one that:
- includes software validated, installed or authorized by the sponsor;
- has the ability to connect to the internet; and
- contains technological characteristics validated, installed or authorized by the sponsor that could be vulnerable to cybersecurity threats.
FDA’s FAQ says the requirements apply to specified premarket submissions: 510(k), PMA, Product Development Protocol, De Novo and HDE, including certain supplements. Manufacturers unsure about their status are told they “may contact the Food and Drug Administration (FDA).”
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What section 524B requires of covered devices
A postmarket vulnerability plan
A plan to monitor, identify and address postmarket vulnerabilities and exploits, including coordinated vulnerability disclosure procedures.
Processes for reasonable assurance of security
Processes and procedures intended to provide reasonable assurance that the device and its related systems are cybersecure.
Updates and patches
Postmarket updates and patches must be made available under the statute’s conditions, and the law distinguishes two cases:
Rank #4
- Known unacceptable vulnerabilities are addressed on a reasonably justified regular cycle.
- Critical vulnerabilities that could cause uncontrolled risks require out-of-cycle updates and patches as soon as possible.
The sources do not set a universal number of days for either case, so beware of any article that quotes one.
A software bill of materials (SBOM)
An SBOM is an inventory of the software inside the device. For cyber devices it must cover commercial, open-source and off-the-shelf components. Its practical value is visibility: when a flaw is disclosed in a widely used component, a manufacturer with an accurate inventory can tell quickly whether its device is affected and which fielded versions need attention.
Best Value
Designing beyond the device itself
FDA’s guidance says “related systems” include manufacturer-controlled elements such as other devices, software functions, update servers and connections to healthcare-facility networks. It recommends that manufacturers consider risks arising from those systems and implement appropriate controls. A device that is well hardened but updated through an exposed server, or trusted by a vulnerable hospital connection, is still at risk.
A lifecycle obligation, not a launch milestone
The guidance recommends keeping documentation such as threat models and cybersecurity risk assessments current as new risks, threats, vulnerabilities, assets or adverse impacts emerge across the total product lifecycle. Changes can also trigger fresh scrutiny. FDA’s FAQ says the information recommended for a device modification depends on the type of change and whether cybersecurity is affected. The guidance gives examples of potentially cybersecurity-impacting changes:
- changes to authentication or encryption;
- new connectivity features;
- changes to software update mechanisms.
Using the framework as a design review lens
FDA’s guidance and the statute point to six questions a design team can ask of any implementation choice. These are an organizing aid, not a compliance checklist, and answering them does not guarantee FDA acceptance.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →| Question | What it probes |
|---|---|
| Patient-safety impact | What harm could result from a compromise, and what residual risk remains? |
| Connectivity and attack surface | Which interfaces and related systems can reach the device? |
| Controls and evidence | Are security controls documented well enough for premarket review? |
| Vulnerability handling | How are vulnerabilities monitored, disclosed and remediated? |
| Update cadence | Can patches be delivered, and how are fielded software versions tracked? |
| Component visibility | Does the SBOM accurately list commercial, open-source and off-the-shelf software? |
Dates worth knowing
- March 29, 2023: section 524B amendments took effect, per FDA.
- February 2026: current FDA final premarket cybersecurity guidance, superseding the June 27, 2025 version, per FDA.
The FDA sources reviewed do not supply an incident-rate or prevalence statistic, so none is cited here.
The Bottom Line
Treat security as a safety property to be designed, evidenced and maintained: choose controls early, account for related systems, document the reasoning, and plan from day one for vulnerability handling, patching and an accurate SBOM. For covered cyber devices in the U.S., several of those steps are legal requirements, not just good practice.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
